Sign in

Keith J. Sullivan

President and Chief Executive Officer at Neuronetics
Board
Since March 7, 2024
Age
65 years
Education
Earned a Bachelor of Business Administration from the College of William and Mary.
Tenure
Has served as Director, President, and CEO of STIM since joining the company on July 14, 2020, with a promotion to the current CEO role on March 7, 2024.

Also at Neuronetics

SF
Stephen Furlong
Executive Vice President, Chief Financial Officer, and Treasurer
WAM
W. Andrew Macan
Executive Vice President, General Counsel, Chief Compliance Officer, and Corporate Secretary

About

Keith J. Sullivan is a seasoned executive in the medical device industry who currently leads STIM as its President and Chief Executive Officer. He assumed an influential leadership role at the company in mid-2020 and subsequently advanced to his current position, underscoring his commitment to driving the organization’s strategic vision.

At 65 years old as of April 11, 2024, he brings over three decades of senior sales and leadership experience to the role. His personal and professional journey is marked by his extensive experience in the industry, contributing significantly to the growth and innovation within the healthcare technology sector.

His career includes key roles at prominent companies, where he held positions such as Chief Commercial Officer and President (North America) at ZELTIQ Aesthetics, along with other senior leadership positions that helped shape his strategic outlook. In addition to his operational roles, he has been instrumental in major strategic initiatives at STIM, including driving expansion efforts that have led to substantial patient engagement and significant industry milestones.

Beyond his executive responsibilities, he also serves on the Boards of Directors for other organizations, further highlighting his broad influence within the healthcare sector. His balanced approach in both leadership and strategic decision-making continues to contribute to his well-regarded professional legacy.

$STIM Performance Under Keith J. Sullivan

Past Roles

OrganizationRoleDate RangeDetails
ZELTIQ Aesthetics, Inc. Chief Commercial Officer and President (North America) January 2016 - April 2017 Developed products under the Coolsculpting® brand; acquired by Allergan, Inc. in April 2017
ZELTIQ Aesthetics, Inc. Senior Vice President and Chief Commercial Officer November 2014 - January 2016 N/A
ZELTIQ Aesthetics, Inc. Senior Vice President of Worldwide Sales and Marketing July 2013 - October 2014 N/A
Medicis Pharmaceuticals Leadership Position N/A Specific title not provided
Reliant Technologies Leadership Position N/A Specific title not provided
Medtronic Leadership Position N/A Specific title not provided
Vision Quest Laser Center Leadership Position N/A Specific title not provided
Coherent Medical Leadership Position N/A Specific title not provided

External Roles

OrganizationRoleDate RangeDetails
Sientra, Inc. Board of Directors N/A N/A
Venus Concept Board of Directors N/A N/A

Fixed Compensation

Data from  FY 2023
Component NameAmountPayment ScheduleAdditional Details
Base Salary$700,000 Effective January 1, 2023; set on February 8, 2023 Determined by the Compensation Committee
Restricted Stock Awards$1,601,700 (285,000 shares) Vests in 3 tranches: one-third at the 1st, 2nd, & 3rd anniversaries of the grant date (Feb 8, 2023) Grant date fair value calculated per ASC Topic 718
Stock Options$0 N/ANo stock options awarded in 2023
Other Compensation$28,485 Paid as incurred in 2023Includes automobile commuting costs ($14,929 with a $529 gross-up) and travel & entertainment expenses ($13,556 with a $3,301 gross-up)

Performance Compensation

Data from  FY 2023

Annual Bonus Performance Compensation

Metric/DetailValue/Description
Performance MetricsCorporate revenue and EBIT objectives
Target Opportunity100% of base salary ($700,000)
Actual Payout94% of target, equaling $660,800
Evaluation PeriodFiscal year 2023, evaluated in early 2024
Thresholds/ConditionsBased on revenue, EBIT performance, market conditions, pilot program (Better Me Guarantee Provider) rollout, and achievement of positive Q4 cash flow
Vesting ScheduleNot applicable (cash bonus)
Additional DetailsPart of the 2023 annual non-equity incentive plan; bonus amount determined at the discretion of the Compensation Committee